Paper Details

  1. Home
  2. Paper Details

Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.

Author: , BrenemanD, CrowleyC, DuvicM, HealdP, HymesK, MartinA G, MyskowskiP, YocumR C

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This open-label study evaluated the safety and efficacy of bexarotene, a novel RXR-selective retinoid, as a single-agent oral therapy for refractory advanced-stage cutaneous T-cell lymphomas (CTCL).
Paper Details　
Original Abstract of the Article :
Cutaneous T-cell lymphomas (CTCL) are malignancies of T cells appearing as skin lesions and are responsive to retinoid therapy. Safety and efficacy of a novel RXR-selective retinoid (rexinoid) bexarotene (Targretin, LGD1069; Ligand Pharmaceuticals Inc, San Diego, CA) was evaluated as a single-agent ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1200/JCO.2001.19.9.2456

データ提供：米国国立医学図書館（NLM）

Bexarotene for Refractory Cutaneous T-Cell Lymphoma: A Multinational Phase II-III Trial

This study ventures into the world of cutaneous T-cell lymphoma (CTCL), a rare and often challenging malignancy. It's like a camel traversing a rugged desert, seeking effective treatments for this complex disease. The research explores the efficacy and safety of bexarotene, a novel retinoid, as a single-agent oral therapy for patients with refractory advanced-stage CTCL.

Finding Hope in the Desert of CTCL: Bexarotene Offers a New Oasis

The study's findings provide encouraging evidence for the use of bexarotene in the treatment of refractory advanced-stage CTCL. The researchers observed significant responses to therapy, indicating that bexarotene can offer a viable treatment option for patients who have not responded to other therapies. While acknowledging the potential for side effects, the authors highlight the overall favorable safety profile of this medication. It's like discovering a new oasis in the desert of CTCL, a place where patients can find relief and hope for a better future.

A New Path for CTCL Treatment: A Journey of Discovery

This research provides valuable insights into the use of bexarotene for refractory advanced-stage CTCL. It highlights the importance of ongoing research to develop new and effective treatments for this challenging malignancy, offering patients a greater chance of survival and a better quality of life. It's like a camel caravan venturing into uncharted territory, seeking new knowledge and therapies to navigate the complex and often unforgiving landscape of CTCL.

Dr. Camel's Conclusion

This study offers a ray of hope for patients with refractory advanced-stage CTCL. Bexarotene has emerged as a potentially effective and safe treatment option, providing a new oasis in the desert of CTCL, offering patients a greater chance of survival and a better quality of life.
Date :
  1. Date Completed 2001-05-31
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

11331325

DOI: Digital Object Identifier

10.1200/JCO.2001.19.9.2456

Related Literature

Article Analysis
・Side Effects of bexarotene
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.